Volume 16

Issue 1

Article 9

2008

Optimal conditions for extraction and simultaneous determination
of sulfamethoxazole and trimethoprim in pharmaceuticals by
micellar electrokinetic capillary chromatography

Follow this and additional works at: https://www.jfda-online.com/journal

Recommended Citation
Injac, R.; Kac, J.; Karljikovic-Rajic, K.; and Strukelj, B. (2008) "Optimal conditions for extraction and
simultaneous determination of sulfamethoxazole and trimethoprim in pharmaceuticals by micellar
electrokinetic capillary chromatography," Journal of Food and Drug Analysis: Vol. 16 : Iss. 1 , Article 9.
Available at: https://doi.org/10.38212/2224-6614.2381

This Original Article is brought to you for free and open access by Journal of Food and Drug Analysis. It has been
accepted for inclusion in Journal of Food and Drug Analysis by an authorized editor of Journal of Food and Drug
Analysis.

18
Journal of Food and Drug Analysis, Vol. 16, No. 1, 2008, Pages 18-25

藥物食品分析

第十六卷

第一期

Optimal Conditions for Extraction and Simultaneous
Determination of Sulfamethoxazole and Trimethoprim
in Pharmaceuticals by Micellar Electrokinetic
Capillary Chromatography
Rade Injac1*, Javor Kac1, Katarina Karljikovic-Rajic2 AND Borut Strukelj1
1.

Faculty of Pharmacy, Institute of Pharmaceutical Biology, University of Ljubljana, Askerceva 7, SI-1000 Ljubljana, Slovenia
Faculty of Pharmacy, Institute of Analytical Chemistry, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia

2.

(Received: November 17, 2006; Accepted: May 8, 2007)

Abstract
A micellar electrokinetic capillary chromatography was performed at 25°C and 30 kV (under pressure of 15 mbar), with 30 mM
borate buffer (pH 9.0), 60 mM sodium dodecysulfate, and 10% (v/v) ethanol as background electrolyte for the determination of sulfamethoxazole and trimethoprim. UV detection was at 205 nm. Recoveries were optimal and acceptable after extraction with ethanol
/ deionized water (1:1, v/v) for both investigated compounds from laboratory mixtures of standards. The method was shown to be
specific, accurate (recoveries were 99.9 ± 0.4% for sulfamethoxazole and 99.8 ± 0.3% for trimethoprim), linear over the tested ranges
(correlation coefficients ≥ 0.9990) and precise (RSD below 0.6%). The method was applied to determine sulfamethoxazole and trimethoprim in tablets, powder for cutaneous use and solution for infusion.
Key words: sulfamethoxazole, trimethoprim, LLE, micellar electrokinetic capillary chromatography (MEKC), pharmaceuticals

INTRODUCTION
Co-trimoxazole is a fixed anti-microbial combination of two chemotherapeutics, sulfonamide sulfamethoxazole (SUL) and trimethoprim (TRI), in a 5:1 (w/w) ratio.
Sulfamethoxazole is an antibiotic of broad spectrum that
competitively inhibits the bacterial enzyme dihydropteroate synthetase. Trimethoprim is a dyhydrofolate-reductase inhibitor that increases activity of SUL. SUL and
TRI are active ingredients in several oral suspensions,
solution for infusion, and solid dosage forms (1).
Pharmaceuticals containing SUL and TRI are usually
analyzed by three principal methods: TLC, spectrophotometry and HPLC. Agbaba et al.(2) developed simultaneous TLC determination of co-trimoxazole as well as
sulfanilamide and sulfanilic acid impurities in pharmaceuticals. SUL and TRI were determined in tablets by ratio
spectra derivative spectrophotometry(3), second derivative
spectrophotometry in the presence of hydroxypropyl-βcyclodextrin(4), first derivative ratio spectrometry(5), and a
flow injection sensor using Sephadex SP C-25 for continuous on-line separation and solid phase UV transduction(6).
Flow-injection spectrophotometric determination was
* Author for correspondence.
Tel: +386-41-964462; Fax: +386-1-4258031;
E-mail: injac@email.com, injacrade@gmail.com

used for sulfadiazine and sulfamethoxazole in pharmaceuticals and urine(7). Lopez-Martinez et al.(8), performed
simultaneous determination of binary mixtures of TRI and
SUL or sulphamethoxypyridazine by the bivariate calibration spectrophotometric method. Different HPLC systems
were used for determination of SUL and/or TRI in suspensions with methyl- and propyl-paraben(9), serum in human
immunodeficiency virus-infected patients(10), bovine milk
using an on-line clean-up column(11), serums in donkeys,
mules and horses(12), and in tablets after preparing SULimprinted polymer in acetonitrile(13). Yang et al.(14)
used LC-MS-MS to determine sulfonamides and tetracyclines in water. LC with a fluorescence detector was
also successfully used for determination of sulfonamide
residues (including SUL) in honey(15), as well as nuclear
magnetic resonance spectroscopy for quantitative analysis of miconazole, metronidazole and sulfamethoxazole in
pharmaceutical and urine samples(16). Molecular imprinting-chemiluminescence determination of TRI using TRIimprinted polymer as recognition material was performed
for tablets and human urine(17).
Capillary electrophoresis (CE) has become an
important liquid separation technique. Capillary zone
electrophoresis was used for determination of SUL,
sulfadiazine and associated compounds in pharmaceutical preparations (18), as well as for determination SUL and
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TRI in human plasma (19). Continuous on-line concentration based on dynamic pH junction for TRI and SUL by
microfluidic capillary electrophoresis combined with flow
injection analysis system was demonstrated through the
separation and determination of SUL and TRI in pharmaceutical preparations (20).
One of the commonly used CE modes is micellar electokinetic capillary chromatography (MEKC). It is efficient for the separation of both ionic and neutral analytes. Success of separation is based mainly on appropriate
selection of the surfactant. Nevado et al.(21) developed a
method for the determination of SUL and TRI and their
main metabolites in human serum by MEKC. They used
20 mM borate buffer (pH 9.3), 25 mM sodium dodecylsulfate (SDS) and 5% (v/v) acetonitrile as electrolyte.
According to previous studies no publications for
determination of SUL and TRI in pharmaceuticals by
MEKC are available.
Experiments in this study have been related to the
effects of different parameters such as influence of pH,
buffer composition, running voltage, running pressure,
concentration of surfactant and organic modifier on the
determination of SUL and TRI by MEKC and the method
validation, as well as influence of different solvent for
extraction on recoveries. The method was tested with
extracts from co-trimoxazole tablets (from Serbia and
Bangladesh), commercial powder mixture Co-trimox®
for cutaneous use (Serbia) and solution for infusion (from
Serbia).

MATERIALS AND METHODS
I. Instruments
An Agilent 3D-CE capillary electrophoresis system
(Waldbronn, Germany) with a diode-array detector and
controlled by HP ChemStation software was used to carry
out MEKC. Compounds were determined on a 56 cm (50
cm to the detector) × 50 µm i.d. fused silica capillary (with
bubble cell, 150 µm) (Agilent, Waldbronn, Germany).
A Metrohm 691 pH meter by Herisau (Switzerland)
was used for pH measurements.
II. Reagents and Solutions
All solvents and reagents were of analytical grade
unless indicated otherwise. Solutions were prepared with
deionized water (Millie-Q-quality). Sulfamethoxazole
and trimethoprim were obtained from Sigma (Deisenhofen, Germany) and Fluka (Buchs, Switzerland), respectively (both USP quality).
Buffer solutions were prepared by dissolving appropriate amount of Na 2B 4O7 in deionized water. The pH
was adjusted to 9.0 with HCl. Sodium dodecylsulphate
(SDS) was from Riedel-de Haën AG (Seelze,Germany).
Na 2B 4O7•10H 2O was p.a. from Kemika (Zagreb, Croatia).

Commercial buffer with 50 mM borate and 100 mM SDS,
pH 9.3 (Agilent, Waldbronn, Germany), was diluted (the
pH was adjusted to 9.0 with HCl) and used for MEKC
method after the determination of optimal conditions.
The background electrolyte (BGE) was 30 mM
borate buffer, pH 9.0, containing 60 mM SDS and 10%
(v/v) ethanol.
III. Preparation of Standard Stock Solutions
Standard stock solutions of SUL and TRI were
prepared by weighing 25 mg of the drugs and dissolving
in 50 mL of ethanol / deionized water (1:1, v/v). Solutions
were stored under refrigeration until use. Solutions were
stable for 7 days and were diluted with running buffer to
obtain the required concentration ranges (0.5-200 mg/L
for both drugs). Solvent previously used for standard
stock solutions preparation, was selected since the same
solvent composition has been confirmed as the best for
extraction of pharmaceutical products.
IV. Samples
The pharmaceutical formulations Co-trimoxazol®
(tablets) containing 400 mg SUL and 80 mg TRI, Cotrim®
(tablets) containing 800 mg SUL and 160 mg TRI,
commercial powder mixture Co-trimox® for cutaneous
use containing SUL:TRI in ratio 5:1 (w/w), and Bactrim®
(ampoules) containing 400 mg SUL and 80 mg TRI per
5 mL ampoule dissolved in ethanol / water for injections
(1:9, v/v) were obtained from Jugoremedija (Zrenjanin,
Serbia), Square Pharmaceuticals LTD Bangladesh (Dhaka,
Bangladesh), SB Trade (Belgrade, Serbia) and Galenika
a.d. (Belgrade - Zemun, Serbia), respectively.
V. Sample Preparation and Extraction
SUL and TRI were extracted from the tablets using
the following procedure. First, 20 tablets from Jugoremedija (average weight 599.62 ± 9.83 mg) or 20 tablets
from Square Pharmaceuticals (average weight 1098.65
± 8.15 mg) were accurately weighed, finely ground to
powder and thoroughly mixed. Amounts corresponding
to 24 mg of declared active principle (calculated as 20 mg
of SUL and 4 mg of TRI), as well as commercial mixture
powder were weighed and transferred into a plastic volumetric flask. Samples were four-fold extracted (4 × 5 mL)
with ethanol / deionized water (1:1, v/v) by shaking and
storage in an ultrasonic bath for 15 min. The extracts
were combined, filtered (0.22 µm nylon filter), transferred
to 25-mL volumetric flask, and filled up with ethanol /
deionized water (1:1, v/v). Different known aliquots (10 –
375 μL) were placed in 1.5 mL calibrated vials and filled
up to volume by automatic pipette with running buffer.
Ampoule of 5 mL with SUL and TRI first was diluted with 5 mL of absolute ethanol, without extraction, and
different known volumes were diluted with running buffer.
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VI. Operating Conditions

II. Optimization of Experimental Conditions

The capillary was conditioned prior to its first use by
flushing with 0.1 M NaOH for 20 min and then with water
for 10 min. The capillary was conditioned using the optimized method at the beginning of each day with methanol
under high pressure for 3 min, water for 0.5 min, and then
rinsed for 2 min with 0.1 M NaOH and 3 min with background electrolyte. Conditioned procedure was followed
by hydrodynamic sample injection at 600 mbars. Assays
were carried out at 30 kV and 25°C (under a running pressure of 15 mbar) in 10 min, and the current was 63-65
µA. The analytes were monitored and quantified at each
maximum absorption wavelength in order to obtain the
maximum signal-to-noise ratio. Accordingly, the selected
wavelengths were 205 and 274 for SUL and 207, 230 and
280 nm for TRI. The selected maximum absorption for
both investigated compounds was at 205 nm.

A preliminary study was carried out using a solution
containing of 25 mg/L SUL and TRI to optimize separation. A 15 mM borate buffer with 30 mM SDS as BGE
was used under temperature and voltage of 25°C and 25
kV, respectively.

RESULTS AND DISCUSSION

According to the 4th European Pharmacopoeia, SUL
is practically insoluble in water, freely soluble in acetone,
sparingly in alcohol and slightly in ether, where as TRI is
very slightly soluble in water and slightly in alcohol(22).
SUL and TRI were usually extracted from pharmaceuticals with ethanol / deionized water mixtures in
different ratios (3,4,6,18,20) or with ethanol / ammonium
buffer solution 2:5 (v/v)(8). Methanol and acetonitrile
were also used as solvents for extraction of SUL and TRI
from pharmaceuticals (9,13).
Influences of organic solvent on recoveries were
developed. Methanol, ethanol and acetonitrile were tested
in concentrations from 0 to 100%. Extraction solutions
were prepared by mixing organic solvent with deionized
water. The influence of organic solvent on the recoveries
is shown in Figure 1. The results demonstrate that type
and percent of solvent have influence on recoveries of SUL
and TRI. A ratio of 1:1 (v/v) ethanol / deionized water was
found to give the best recoveries for both drugs.

At low concentration of surfactant, the main problem was the same or very similar migration times of
investigated compounds. The peaks in preliminary studies overlapped and showed shoulders with higher SDS
concentration. Also, the symmetry of the peaks was not
good. Addition of organic modifier can be essential for
purity of peak and quality of separation. Ethanol (Figure
2A), methanol (Figure 2B) and acetonitrile (Figure 2C)
were tested in concentrations from 0 to 15%. The presence of a 10% (v/v) of ethanol in the BGE resulted in
better resolution and removal of shoulders (Figure 3).
SDS concentration was tested from 10 to 100 mM, and a
concentration of 60 mM was found to give the best shape
and resolution (Figure 4).
C. Influence of Running Pressure, Voltage and Temperature
Running pressure was tested in the range 0-30 mbar
using the above experimental conditions. Migration times
were slightly decreased, with increasing pressure. Optimal
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The influence of pH was examined over the range
of 6.0 to 10.0 using phosphate buffer and borate buffer,
respectively, as electrolyte in deionised water and adjusting with HCl or NaOH to the required pH. The results
show that determination was best at pH 9.0 with borate
buffer. The borate and phosphate buffers were varied
from 5 to 50 mM using the experimental conditions
mentioned above. A 30 mM concentration of borate
buffer was considered suitable peak shape without shoulders, as well as the best resolution of peaks.
B. Influence of the Organic Modifier and SDS Concentration

I. Optimization of Extraction Conditions
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Figure 1. Influence of organic solvent on recovery of (A) SUL and (B) TRI, for extraction from pharmaceuticals.
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Figure 2. Effect of: (A) ethanol, (B) methanol, (C) acetonitrile, as
organic modifier on migration time and composition of separation
SUL and TRI. The BGE was 30 mM borate buffer, pH 9.0, containing
60 mM SDS, the temperature and voltage were 25°C and 30 kV,
respectively, with running pressure of 15 mbar.
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Figure 3. Effect of ethanol concentration (5, 10 and 15%, v/v) in 30 mM borate buffer, pH 9.0, containing 60 mM SDS. Temperature and
voltage were 25°C and 30 kV, respectively, with running pressure of 15 mbar. UV detection was set at 205 nm. Electropherograms were
obtained for 0.2 mg/mL of SUL and 0.04 mg/mL of TRI from pharmaceuticals.

22
Journal of Food and Drug Analysis, Vol. 16, No. 1, 2008

pressure of 15 mbar was selected and gives an acceptable
level of baseline noise and the best symmetric peaks.
A BGE of 30 mM borate (pH 9.0), containing 60 mM
sodium dodecylsulphate and 10% (v/v) ethanol, without running pressure at 25°C, was used for the determination of running voltages effects in the range 5-30 kV.
An acceptable level of baseline noise was achieved by
performing experiments at 25°C and 30 kV.
A micellar electrokinetic capillary chromatography
was performed at 25°C and 30 kV (under pressure of 15
mbar), using 30 mM borate buffer (pH 9.0) containing 60
mM sodium dodecysulfate (SDS) and 10% (v/v) ethanol,
as background electrolyte for separation of SUL and TRI
with resolution of 2.4 and 1.6 for standards (Figure 5A)
and tested samples (Figure 5B), respectively. UV detection was carried out at 205 nm. From the data obtained
at 205 nm, the electrophoretic mobilities of SUL and TRI
in standard solutions were 1.63 × 10 -4 cm 2/Vs and 1.54 ×
10 -4 cm 2/Vs, as well as in test samples were 1.62 × 10 -4
cm 2/Vs and 1.51 × 10 -4 cm 2/Vs, respectively.

III. Validation of the Test Method
Validation procedures were those described in USP
24(23), the International Conference of Harmonization
(ICH) Guidelines (24,25), and other literature (26-28).
(1) Selectivity
Selectivity of the method was investigated by
observing interfering peaks from matrix present in the
pharmaceuticals. Four different matrices were tested.
There was no interference in MEKC results by the matrices ingredients in any of the tested sample, indicating
that the method is selective (Figure 5).
(II) Linearity
Linearity of the assay was determined by analysis of
at least five different concentrations of standards (24,25).
Linearity was checked in range 0.5 to 200 mg/L for each
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Figure 4. Effect of SDS concentration (20 – 100
mM) in 30 mM borate buffer, pH 9.0, containing
10% (v/v) ethanol. Temperature and voltage were
25°C and 30 kV, respectively, with running pressure
of 15 mba r. U V det e ct ion wa s set at 205 n m.
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Figure 5. Electropherograms obtained for (A) 0.05 mg/mL of both standards (B) 0.2 mg/mL of SUL and 0.04 mg/mL of TRI from
pharmaceuticals; under the optimized conditions, at 205 nm. The BGE was 30 mM borate buffer, pH 9.0, containing 60 mM SDS and 10% (v/v)
ethanol, the temperature and voltage were 25°C and 30 kV, respectively with running pressure of 15 mbar.
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investigated compound (0.5, 5.0, 10.0, 25.0, 50.0, 75.0,
100.0, 125.0, 150.0 and 200.0 mg/L). Linearity of calibration the curves (peak area vs. concentration) for SUL and
TRI was established across the concentration ranges 6.5
– 100.0 mg/L and 4.0 – 102.5 mg/L with correlation coefficients of 0.9990 and 0.9992, respectively (Table 1).
(III) Limit of Detection (LOD) and Limit of Quantification
(LOQ)
LOD and LOQ were estimated by the baseline noise
method. Baseline noise was evaluated by recording the
detector response over a period of ten times the peak
width. LOD and LOQ, were defined as the analyte concentrations resulting in peaks of height three and ten times the
baseline noise level, respectively(29). LOD and LOQ are
1.3 mg/L for TRI and 1.8 mg/L for SUL and 3.4 mg/L for
TRI and 5.9 mg/L for SUL, respectively (Table 1).

(VII) Robustness
The optimum MEKC conditions set for this method
have been slightly modified in order to evaluate the
robustness. The effects of different concentrations of
SDS (30 ± 1 mM), organic modifier (10 ± 0.5% ethanol)
in the BGE, buffer pH (9.0 ± 0.06), capillary temperature (25 ± 5°C), running pressure (15 ± 1 mbar), running
voltage (30 ± 1 kV), and detection wavelength (± 3 nm)
were determined. The fractional factorial design (29) was
applied. No significant variations in accuracy, specificity
and precision were found over the tested ranges, which
indicated that the method conditions are robust.

Table 1. Statistical parameters of the calibration curve for SUL and
TRI (linear regression), with LODs and LOQs

(IV) Accuracy and Precision
Accuracy of the method was determined by analyzing solutions of known concentrations (working standard solutions) and comparing the measured and known
values. The mean recoveries for SUL and TRI were
99.9 ± 0.4% and 99.8 ± 0.3% (n = 5 for each of presented
concentration), proving a good accuracy of the method
(Table 2).
Although precision can be measured as repeatability, reproducibility, and intermediate precision, this study
investigated only repeatability and intermediate precision.

SUL

TRI

Intercept

17.268 ± 3.2

-21.335 ± 4.5

Slope

6570.7 ± 17.3

11835.0 ± 23.1

Correlation coefficient

0.9990

0.9992

Linear range (mg/L)

6.5 – 100.0

4.0 – 102.5

LOD (mg/L)

1.8

1.3

LOQ (mg/L)

5.9

3.4

Table 2. Determination of accuracy in samples of known concentration of SUL and TRI
Theoretical
concentration
(mg/L)

(V) Repeatability
A repeatability test was performed to determine
intra-day variation in peak’s areas and migration times.
Standard solutions of concentrations 25, 50 and 100 mg/
L (n = 6) were analyzed (Table 3). The RSD values for
migration times (0.15% for SUL and 0.25% for TRI) and
for peak areas (0.19-0.57% SUL, 0.31-0.36% TRI) indicate that repeatability of the method is acceptable.

Experimental
concentration (mg/L)
SUL

TRI

SUL

TRI

10

9.98

9.95

99.80

99.50

20

19.94

19.96

99.70

99.80

30

30.11

29.87

100.37

99.57

40

39.79

40.07

99.48

100.17

50

50.13

50.01

100.26

100.02

Mean ± SD 99.92 ± 0.38 99.81 ± 0.29

(VI) Intermediate Precision
Intermediate precision was evaluated over three days
(inter-day repeatability) using working solutions (concentrations 10-100 mg/L). These solutions were injected
daily under the same conditions and the results were used
for the repeatability study. The solutions were stored
at room temperature (25 ± 2°C) in sunlight, decreasing
recovery values from 99.9 to 98.3% for SUL and 100.1
to 97.5% for TRI in ethanol / deionized water (1:1, v/
v). When stored in refrigerator in the dark, the recovery ranged from 100.1 to 99.5% over three days for both
drugs. The RSD values (0.11-0.24% for SUL and 0.130.29% for TRI) indicate that the intermediate precision is
acceptable.

Recovery
(%)

Table 3. Determination of repeatability

SUL

TRI
a

Theoretical
concentration (mg/L)

Migration
timea (min)

Peak areaa
(mAUs)

25

8.546 ± 0.009

181.29 ± 0.34

50

8.542 ± 0.013

342.45 ± 4.73

100

8.555 ± 0.011

677.04 ± 3.83

25

9.217 ± 0.012

275.45 ± 0.86

50

9.196 ± 0.027

569.41 ± 2.09

100

9.171 ± 0.018

1162.89 ± 4.12

Mean ± SD (n = 6).
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Table 4. Application results
Tested sample
®

Co-trimoxazol
®

Cotrim

®

Co-trimox

®

Bactrim

Amount expected (mg)

Amount found (mg)

Recovery (%)

SUL

TRI

SUL

TRI

SUL

TRI

400

80

406.5 ± 0.8

81.9 ± 0.3

101.63

102.38

800

160

804.1 ± 0.6

164.9 ± 0.4

100.51

103.06

5

1

4.9 ± 0.1

1.0 ± 0.1

98.00

100.00

400

80

399.8 ± 0.2

79.7 ± 0.4

99.95

99.63

III. Drugs Stability
Stability of SUL and TRI in ethanol / deionized
water (1:1, v/v) solutions was checked at room temperature (25 ± 2°C) for 72 hr and the recoveries were 101.2
± 0.3% and 100.8 ± 0.4%, respectively. Stability in the
same above mentioned solvent was also checked at 72
hr at 4°C (refrigerator). Recovery was 100.1 ± 0.2% for
SUL and 99.9 ± 0.2% for TRI, indicating good stability.
For exact results, samples have to be prepared in ethanol
/ deionized water (1:1, v/v) and refrigerated until usage.
IV. Application
The proposed assay method of investigated
compounds was applied for quality control of different
pharmaceutical products. The Serbian pharmaceutical
industry currently has three different commercial formulations containing SUL and TRI, tablets, commercial
powder mixture for cutaneous use and solution for infusion. Also, tablets from Bangladesh have been analyzed
for the comparison with European products.
In the analysis of the commercial products, the found
amounts and recoveries were determined by calibration
curves of standards solution. The results show agreement
between the declared and found values (Table 4).
The advantage of this method over the HPLC and
TLC methods described in literature (2,9,13) for analysis
SUL and TRI in pharmaceuticals is its lower running
costs and higher environmental friendliness. An HPLC
analysis with flow-rate of 1.0 (13) or 1.8(9) mL/min and
analysis time of 15 min each, requires 15 or 27 mL of
acetonitrile/water or acetonitrile/water/triethanolamine
as the mobile phase, respectively. In the developed and
proposed method, 20-30 analyses with MEKC require 3
mL of borate buffer containing SDS and 10% (v/v) ethanol, while 20 analyses by HPLC require 300 or 540 mL
of mobile phase. Another advantage of proposed method
over SPF methods (3,4,8) for analysis SUL and TRI in
pharmaceuticals is better accuracy of MEKC. On the
other hand, a disadvantage of developed MEKC method
is lower sensitivity in contrast to SPF methods.

CONCLUSIONS
The new experimental condition for MEKC is
presented as a useful technique for rapid determination of
SUL and TRI using SDS as surfactant (60 mM) and ethanol 10% (v/v) as organic modifier and borate buffer (30
mM, pH 9.0). A running pressure of 15 mbar was applied
and it gives the best shape of peaks. This system was
also applied successfully to their SUL and TRI identification and determination in pharmaceuticals as tablets,
powder and solution for infusion. Ethanol / deionized
water (1:1, v/v) was essential for efficient extraction and
recoveries over 99.8% for both analysed drugs.
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